Pharma giant Pfizer ($PFE) is making progress in the Phase II trial of a vaccine for meningitis serogroup B, for which there are no such preventive treatments available. This week the New York-based drugmaker's trial got some ink from media near some of the study sites in the Midwest. "This is an important type of (meningitis), and therefore a vaccine is absolutely required," said Emilio Emini, Pfizer's chief scientific officer for vaccine research, as quoted by The Detroit News. The company hopes to launch a Phase III study of the vaccine by the end of the year. Article